EVALUATION OF MINIMAL RESIDUAL DISEASE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH VENETOCLAX OR PLACEBO IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE: BELLINI STUDY ANALYSES

EHA Library, Philippe Moreau, 294892

IXAZOMIB-BASED THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) PATIENTS (PTS) TREATED VIA AN EARLY ACCESS PROGRAM (EAP) IN EUROPE: THE ‘USE VIA EARLY ACCESS TO IXAZOMIB' (UVEA-IXA) STUDY

EHA Library, Heinz Ludwig, 294893

NEXT-GENERATION SEQUENCING OF VJ LIGHT CHAIN REARRANGEMENTS IN CELL-FREE DNA FOR MONITORING MULTIPLE MYELOMA

EHA Library, Elisabeth Mack, 294894

ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: ICARIA-MM SUBGROUP ANALYSIS

EHA Library, Meral Beksac, 294895

DARATUMUMAB BASED THERAPY FOR PATIENTS WITH MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE

EHA Library, Efstathios Kastritis, 294896

LENALIDOMIDE AND DEXAMETHASONE PLUS OR MINUS CLARYTHROMYCIN IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION: UPDATED RESULTS OF THE GEM-CLARIDEX TRIAL

EHA Library, Noemi Puig, 294897

ROLE OF SERUM FREE LIGHT CHAIN ASSAY FOR DEFINING RESPONSE AND PROGRESSIVE DISEASE IN IMMUNOGLOBULIN SECRETORY MULTIPLE MYELOMA

EHA Library, Paola Tacchetti, 294898

POMALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (POMCIDEX), FOR THE TREATMENT OR RELAPSE AND REFRACTORY MULTIPLE MYELOMA (RRMM): REAL-WORLD ANALYSIS OF THE PETHEMA-GEM EXPERIENCE.

EHA Library, Paula Rodríguez-Otero, 294899

UPDATES FROM A PHASE IB STUDY OF ISATUXIMAB, BORTEZOMIB AND DEXAMETHASONE PLUS CYCLOPHOSPHAMIDE OR LENALIDOMIDE IN TRANSPLANT INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Enrique Maria Ocio San Miguel, 294900

EFFICACY AND SAFETY OF DARATUMUMAB WITH DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: PRELIMINARY RESULTS OF THE PHASE 2 DARE STUDY

EHA Library, Efstathios Kastritis, 294901

CORRELATION OF TUMOR BCMA EXPRESSION WITH RESPONSE AND ACQUIRED RESISTANCE TO IDECABTAGENE VICLEUCEL IN THE KARMMA STUDY IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA

EHA Library, Nathan Martin, 294902

CORRELATION AND PROGNOSTIC VALUE OF QUANTIFICATION OF TUMOR VOLUME BY BONE MARROW BIOPSY, METABOLIC TUMOR VOLUME, AND TOTAL DIFFUSION VOLUME IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Toshiki Terao, 294903

MOBILIZATION OF AUTOLOGOUS STEM CELLS UNDER INDUCTION THERAPY WITH ISATUXIMAB, CARFILZOMIB, LENALIDOMIDE, DEXAMETHASONE (ISA-KRD) IN HIGH-RISK MYELOMA PATIENTS: FIRST RESULTS OF THE GMMG-CONCEPT TRIAL

EHA Library, Anne-Marie Asemissen, 294904

PHASE 3 STUDY OF DARATUMUMAB/BORTEZOMIB/DEXAMETHASONE (D-VD) VERSUS BORTEZOMIB/DEXAMETHASONE (VD) IN CHINESE PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): MMY3009 (LEPUS)

EHA Library, Xiaojun Huang, 294905

NEUTROPHILS-TO-LYMPHOCYTE RATIO AND IGM CONCENTRATION CAN PREDICT TIME TO PROGRESSION IN PATIENTS AFFECTED BY NON-IGM MGUS: RESULTS FROM A RETROSPECTIVE STUDY AT A SINGLE INSTITUTION

EHA Library, Alessandra Romano, 294906

AL AMYLOIDOSIS SCREENING USING ABDOMINAL FAT PAD BIOPSY AND NT-PROBNP LEVELS IN MGUS PATIENTS: A RETROSPECTIVE REVIEW OF LOCAL EXPERIENCE

EHA Library, Holly Lee, 294907

CLINICAL PREDICTORS OF PROGRESSION-FREE SURVIVAL IN MULTIPLE MYELOMA PATIENTS TREATED WITH ANTI-BCMA CAR-T CELLS

EHA Library, Sandy Wong, 294908

FINAL ANALYSIS OF A RANDOMIZED PHASE II STUDY FOR OPTIMIZING MELPHALAN, PREDNISOLONE AND BORTEZOMIB IN TRANSPLANT-INELIGIBLE UNTREATED MULTIPLE MYELOMA: JAPAN CLINICAL ONCOLOGY GROUP STUDY (JCOG1105)

EHA Library, Dai Maruyama, 294909

DYNAMICS IN THE CHOICE OF TREATMENT FOR PATIENTS WITH MULTIPLE MYELOMA – RESULTS FROM THE MYRIAM REGISTRY

EHA Library, Monika Engelhardt, 294911

THE IMPACT OF CHANGED TREATMENT PATTERNS IN MULTIPLE MYELOMA ON HEALTH-ECONOMIC COSTS, MYELOMA COMPLICATIONS AND SURVIVAL; A POPULATION BASED COMPARISON BETWEEN TWO TIME PERIODS IN DENMARK.

EHA Library, Louise Hur Hannig, 294912

THROMBOTIC AND BLEEDING COMPLICATIONS IN PATIENTS WITH AL AMYLOIDOSIS

EHA Library, Efstathios Kastritis, 294913

TREATMENT PATTERNS AND SURVIVAL OUTCOMES OF ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: RESULTS FROM THE CONNECT® MM REGISTRY

EHA Library, Hans Lee, 294914

IXAZOMIB-DEXAMETHASONE VS PHYSICIAN'S CHOICE IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY SYSTEMIC AL AMYLOIDOSIS (AL) BY PRIOR PROTEASOME INHIBITOR EXPOSURE IN THE PHASE 3 TOURMALINE-AL1 TRIAL

EHA Library, Efstathios Kastritis, 294915

PREDICTORS OF EARLY RELAPSE IN YOUNG MULTIPLE MYELOMA PATIENTS: INTEGRATED ANALYSIS OF BASELINE FEATURES AND ACHIEVEMENT OF MINIMAL RESIDUAL DISEASE NEGATIVITY

EHA Library, Francesca Gay, 294916

AN INTACT GUT MICROBIOME PROTECTS GENETICALLY PREDISPOSED MICE AGAINST LEUKEMIA

EHA Library, Carolina Vicente-Dueñas, 294920

POSITRON EMISSION TOMOGRAPHY GUIDED OMISSION OF RADIOTHERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE III HD17 TRIAL BY THE GHSG

EHA Library, Peter Borchmann, 294921

TBI OR CHEMOTHERAPY BASED CONDITIONING FOR CHILDREN AND ADOLESCENTS WITH ALL: A PROSPECTIVE RANDOMIZED MULTICENTER-STUDY 'FORUM' ON BEHALF OF THE AIEOP-BFM-ALL-SG, IBFM-SG, INTREALL-SG AND EBMT-PD-WP

EHA Library, C Peters, 294922

NETRIN-1 REGULATES HEMATOPOIETIC STEM CELL DORMANCY AND FUNCTION VIA ITS RECEPTOR NEOGENIN WITH IMPLICATIONS FOR STEM CELL AGEING

EHA Library, Simon Renders, 294923

A NOVEL ROLE FOR IRON REGULATORY PROTEINS IN HEMATOPOIESIS

EHA Library, Bruno Galy, 294924

INDUCIBLE PHASE SEPARATION OF GSK3A MEDIATES ASPARAGINASE RESISTANCE IN ACUTE LEUKEMIAS

EHA Library, Laura Hinze, 294925

MEF2C DRIVES A MIXED PHENOTYPE ETP-ALL BY ACTIVATING B CELL GENES IN AN EARLY T CELL CONTEXT

EHA Library, Kirsten Canté-Barrett, 294926

BETTING ON PRC2 ALTERATION IN T CELL ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Guillaume Andrieu, 294927

MLL-AF4 RECRUITS H3K79ME2 VIA PAF1 DURING LEUKAEMIC TRANSFORMATION IN A NOVEL MODEL OF HUMAN FETAL LIVER-DERIVED T(4;11) INFANT ALL

EHA Library, Siobhan Rice, 294928

LONGITUDINAL MULTI-OMICS ANALYSIS OF 13 MATCHED SAMPLE PAIRS COLLECTED FROM PEDIATRIC T-CELL LEUKEMIA PATIENTS AT INITIAL DIAGNOSIS AND AT RELAPSE

EHA Library, Paulina Richter-Pechanska, 294929

RECURRENT PAX5 FUSIONS IN MLL-GERMLINE INFANT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Giovanni Cazzaniga, 294930

SELECTIVE BLOCKADE OF ONCOGENIC NOTCH1 WITH THE NEW SERCA INHIBITOR CAD204520

EHA Library, Matteo Marchesini, 294931

TOWARDS MOLECULAR STRATIFICATION OF PAEDIATRIC T-CELL LYMPHOBLASTIC LYMPHOMAS BASED ON MINIMAL DISSEMINATED DISEASE AND NOTCH1/FBXW7 MUTATIONAL STATUS: THE FRENCH EURO-LB02 EXPERIENCE

EHA Library, Amelie Trinquand, 294932

MULTICOLOR FLOW CYTOMETRY PANEL WITH CCD79A GATING TO DETECT MINIMAL RESIDUAL DISEASE IN PATIENTS WITH B-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA POST ANTI-CD19 CAR-T THERAPY BRIDGING TO ALLO-HSCT

EHA Library, Hui Wang, 294933

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOLLOWING DASATINIB-BASED TWO-STEP INDUCTION FOR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: RESULTS OF THE JALSG PH+ALL213 STUDY

EHA Library, Isamu Sugiura, 294934

FIRST-IN-HUMAN, UNIVERSAL ANTI-CD7 CAR-T THERAPY FOR RELAPSED AND REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R T-ALL)

EHA Library, Xinxin Wang, 294935

VENETOCLAX AND NAVITOCLAX IN RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOBLASTIC LYMPHOMA

EHA Library, Elias Jabbour, 294936

IMPROVED OUTCOME FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) AND AN ABL-CLASS FUSION FOLLOWING TREATMENT WITH A TYROSINE KINASE INHIBITOR: PRELIMINARY DATA FROM UKALL2011

EHA Library, Anthony Moorman, 294937

TISAGENLECLEUCEL FOR PEDIATRIC/YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: PRELIMINARY REPORT OF B2001X FOCUSING ON PRIOR EXPOSURE TO BLINATUMOMAB AND INOTUZUMAB

EHA Library, Andre Baruchel, 294938

ALLCAR19: UPDATED DATA USING AUTO1, A NOVEL FAST-OFF RATE CD 19 CAR IN RELAPSED /REFRACTORY B-ACUTE LYMPHOBLASTIC LEUKAEMIA

EHA Library, Claire Roddie, 294939

DISRUPTION OF SERINE METABOLISM IS A NOVEL THERAPEUTIC STRATEGY IN FMS-LIKE TYROSINE KINASE 3 (FLT3) MUTANT ACUTE MYELOID LEUKAEMIA

EHA Library, Stefan Bjelosevic, 294940

MIR-125B-MEDIATED TARGETING OF ARID3A PROMOTES THE PROGRESSION OF MYELOID LEUKEMIA

EHA Library, Oriol Alejo-Valle, 294941

HIF2ALPHA PARTAKES TO AML DIFFERENTIATION BLOCKADE, AND ITS INHIBITION DRIVES AML DIFFERENTIATION

EHA Library, Daniela Magliulo, 294942

THROMBOPOIETIN RECEPTOR ACTIVATION BY A DOWN SYNDROME MYELOID LEUKEMIA VARIANT OF THE COMMON BETA CHAIN OF THE IL3, IL5 AND GM-CSF SIGNALLING COMPLEXES

EHA Library, Leila Varghese, 294943

ATF3 REGULATES SERINE SYNTHESIS AND CATABOLISM TO SUPPORT AGGRESSIVE SUB-TYPES OF ACUTE MYELOID LEUKEMIA

EHA Library, Stephen Sykes, 294944

ELUCIDATION OF THE ONCOGENIC EVI1 SUPERENHANCER COMPLEX IN INV(3)/T(3;3) LEUKEMIA

EHA Library, Sandra Kiehlmeier, 294945

A SINGLE NUCLEOTIDE POLYMORPHISM OF THE TRANSCRIPTION FACTOR GROWTH FACTOR INDEPENDENCE 1 (GFI1) ACCELERATES AML EVOLUTION AND SENSITIZES AML CELLS TO TREATMENT WITH DNA REPAIR INHIBITORS

EHA Library, Daria Frank, 294946

CONCURRENT LOSS OF BCOR AND DNMT3A PROMOTES ACUTE ERYTHROID LEUKEMIA (AEL) IN MICE

EHA Library, Paolo Sportoletti, 294947

PAUSED TRANSCRIPTION, A NOVEL MIR139 SILENCING MECHANISM DOWNSTREAM OF MLL-AF9 IN ACUTE MYELOID LEUKEMIA

EHA Library, Christiaan J. Stavast, 294948

A MOUSE MODEL REVEALING THE TUMOR SUPPRESSIVE ACTIVITY OF GATA2

EHA Library, Avigail Rein, 294949

NOVEL INSIGHTS INTO GENOMIC CLASSIFICATION AND PROGNOSIS IN ACUTE MYELOID LEUKEMIA BASED ON A PAN-EUROPEAN PUBLIC-PRIVATE PARTNERSHIP, THE HARMONY ALLIANCE

EHA Library, Lars Bullinger, 294950

THE NATURAL HISTORY AND FITNESS LANDSCAPE OF CLONAL HEMATOPOIESIS

EHA Library, Margarete Fabre, 294951

EXPRESSION OF THE EPITHELIAL TO MESENCHYMAL TRANSITION MODULATOR SNAI1 IN ACUTE MYELOID LEUKEMIA - A MODEL OF LSD1 CORRUPTION

EHA Library, Catherine Carmichael, 294952

FUNCTIONAL CHARACTERIZATION OF PRE-LEUKEMIC HEMATOPIOETIC CELLS

EHA Library, Liran Shlush, 294953

PATIENT-DERIVED XENOGRAFT MODELS OF ACUTE MYELOID LEUKEMIA FOR THE PRECLINICAL CHARACTERIZATION OF CD33.CAR-CIK CELLS ENGINEERED BY USING A LATEST VERSION OF THE SLEEPING BEAUTY TRANSPOSON SYSTEM

EHA Library, Maria Caterina Rotiroti, 294954

A SINGLE VERSUS FRACTIONATED SCHEDULE OF GEMTUZUMAB OZOGAMICIN IN COMBINATION WITH DAUNORUBICIN / ARA-C AS INDUCTION THERAPY IN OLDER PATIENTS WITH AML: RESULTS FROM THE UK NCRI AML18 TRIAL

EHA Library, Nigel Russell, 294955

A PHASE 3 STUDY OF VENETOCLAX PLUS LOW-DOSE CYTARABINE IN PREVIOUSLY UNTREATED OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (VIALE-C): A 6-MONTH UPDATE

EHA Library, Andrew H. Wei, 294956

A RANDOMISED EVALUATION OF LOW-DOSE ARA-C PLUS AC220 (QUIZARTINIB) VERSUS LOW DOSE ARA-C IN OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE LI-1 TRIAL

EHA Library, Mike Dennis, 294957

ALL-TRANS RETINOIC ACID IMPROVES SURVIVAL IN ELDERLY AML PATIENTS BY DELAYING DECITABINE RESISTANCE DEVELOPMENT: RESULTS OF A RANDOMIZED TRIAL (DECIDER STUDY)

EHA Library, Michael Lübbert, 294958

ENASIDENIB PLUS AZACITIDINE SIGNIFICANTLY IMPROVES COMPLETE REMISSION AND OVERALL RESPONSE RATES VERSUS AZACITIDINE MONOTHERAPY IN MUTANT-IDH2 NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (ND-AML)

EHA Library, Courtney DiNardo, 294959

POSTTRANSPLANT MAINTENANCE THERAPY IN PATIENTS WITH FLT3-MUTATED (FLT3MUT+) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM A RETROSPECTIVE CHART REVIEW STUDY

EHA Library, James D. Griffin, 294960

10-DAY DECITABINE AND VENETOCLAX (DEC10-VEN) VS. INTENSIVE CHEMOTHERAPY (IC) IN ACUTE MYELOID LEUKEMIA (AML): A PROPENSITY SCORE MATCHED ANALYSIS STRATIFIED BY RISK OF TREATMENT-RELATED MORTALITY

EHA Library, Abhishek Maiti, 294961

COMPARATIVE RESULTS OF AZACITIDINE AND DECITABINE FROM A LARGE PROSPECTIVE PHASE 3 STUDY IN TREATMENT NAÏVE ACUTE MYELOID LEUKEMIA (TN-AML) NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

EHA Library, Amer M. Zeidan, 294962

PHASE IB/II STUDY OF THE IDH1-MUTANT INHIBITOR IVOSIDENIB WITH THE BCL2 INHIBITOR VENETOCLAX +/- AZACITIDINE IN IDH1-MUTATED HEMATOLOGIC MALIGNANCIES

EHA Library, Courtney DiNardo, 294963

THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IS WELL-TOLERATED AND EFFECTIVE IN AML PATIENTS: PHASE 1B RESULTS

EHA Library, Naval Daver, 294964

TEMPORAL TRENDS IN OVERALL SURVIVAL AMONG ADULT NON-APL AML PATIENTS IN THE PERIOD 2000-2016: A DANISH POPULATION-BASED STUDY

EHA Library, Lasse Hjort Jakobsen, 294965

PROGNOSTIC SIGNIFICANCE OF CONCOMITANT GENE MUTATIONS IN INTENSIVELY TREATED PATIENTS WITH IDH1/2 MUTATED AML

EHA Library, Matthieu Duchmann, 294966

EMERGING MUTATIONS AT RELAPSE IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WHO RECEIVED GILTERITINIB THERAPY IN THE PHASE 3 ADMIRAL TRIAL

EHA Library, Catherine C. Smith, 294967

MOLECULAR LANDSCAPE AND PROGNOSTIC IMPACT OF FLT3 INTERNAL TANDEM DUPLICATION INSERTION SITE IN ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE RATIFY STUDY (ALLIANCE 10603)

EHA Library, Frank Rücker, 294968

FIRST-IN-HUMAN CLL1-CD33 COMPOUND CAR (CCAR) T CELL THERAPY IN RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA

EHA Library, Fang Liu, 294969

MULTI-OMICS DATA INTEGRATION IDENTIFIES IGHV-INDEPENDENT BIOMARKER ASSOCIATED WITH MTOR-MYC-OXPHOS FOR AGGRESSIVE CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Junyan Lu, 294970

DETERMINANTS OF THE PROTEOME LANDSCAPE IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Fabienne Meier-Abt, 294971

MIR-29 INFLUENCES CD40 SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Sonali Sharma, 294972

ACTIVE AKT SIGNALING TRIGGERS CLL TOWARDS RICHTER'S TRANSFORMATION VIA OVER-ACTIVATION OF NOTCH1

EHA Library, Stuart Blakemore, 294973

MECHANISMS OF ADAPTATION TO IBRUTINIB IN HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Gabriela Forestieri, 294974

FIXED-DURATION VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: FOLLOW-UP OF EFFICACY AND SAFETY RESULTS FROM THE MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE 3 CLL14 TRIAL

EHA Library, Othman Al-Sawaf, 294975

EFFICACY OF VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: PRIMARY ENDPOINT ANALYSIS OF THE INTERNATIONAL PHASE 3B TRIAL (VENICE I)

EHA Library, Arnon P. Kater, 294976

CLL2-GIVE, A PROSPECTIVE, OPEN-LABEL, MULTICENTER PHASE-II TRIAL OF OBINUTUZUMAB (GA101, G), IBRUTINIB (I), PLUS VENETOCLAX (VE) IN UNTREATED PATIENTS WITH CLL WITH 17P DELETION / TP53 MUTATION

EHA Library, Henriette Huber, 294977

FIRST-LINE IBRUTINIB (IBR) + VENETOCLAX (VEN) FOR PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): EFFICACY AND SAFETY RESULTS FROM CAPTIVATE MRD COHORT

EHA Library, Tanya Siddiqi, 294978

ACALABRUTINIB VS IDELALISIB PLUS RITUXIMAB (IDR) OR BENDAMUSTINE PLUS RITUXIMAB (BR) IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): ASCEND FINAL RESULTS

EHA Library, Paolo Ghia, 294979

A TIME-LIMITED TREATMENT WITH IBRUTINIB ALONG WITH A REDUCED NUMBER OF IMMUNOCHEMOTHERAPY COURSES LEADS TO PROFOUND AND LONG-LASTING RESPONSES IN PREVIOUSLY UNTREATED CLL PATIENTS

EHA Library, Anne-Sophie Michallet, 294980

BTK AND PLCG2 MUTATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RELAPSING ON IBRUTINIB: A EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC) STUDY BASED ON REAL-WORLD EVIDENCE

EHA Library, Lydia Scarfò, 294981

INITIAL RESULTS OF A MULTICENTER, INVESTIGATOR-INITIATED STUDY OF MRD DRIVEN TIME LIMITED THERAPY WITH ZANUBRUTINIB, OBINUTUZUMAB AND VENETOCLAX

EHA Library, Jacob D. Soumerai, 294982

ACALABRUTINIB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA: MATURE RESULTS FROM PHASE 2 STUDY DEMONSTRATING DURABLE REMISSIONS AND LONG-TERM TOLERABILITY

EHA Library, John C. Byrd, 294983

KINETICS OF RESPONSE IN THE PERIPHERAL BLOOD PREDICTS LONG TERM RESPONSES TO IBRUTINIB + VENETOCLAX TREATMENT FOR RELAPSED/REFRACTORY CLL IN THE BLOODWISE TAP CLARITY TRIAL.

EHA Library, Andrew Rawstron, 294984

IDENTIFICATION OF A DRUG-ABLE DOPAMINE RECEPTOR MEDIATED PATHWAY THAT IS CRITICAL FOR CML STEM CELL SURVIVAL

EHA Library, Jake Ritchie, 294985

MODEL-BASED INFERENCE AND CLASSIFICATION OF IMMUNOLOGICAL CONTROL MECHANISMS FROM TKI CESSATION AND DOSE REDUCTION IN CML PATIENTS

EHA Library, Ingmar Glauche, 294986

MECHANISTIC AND THERAPEUTIC INSIGHTS INTO PRC2 REPROGRAMMING IN BLAST PHASE CML

EHA Library, Rebecca Mitchell, 294987

MECHANISTIC INSIGHTS INTO THE INHIBITION OF T REGULATORY CELLS BY DASATINIB IN CML PATIENTS WITH CLONAL LYMPHOCYTOSIS

EHA Library, Patrick Harrington, 294988

PERIPHERAL BLOOD CD26+ LEUKEMIA STEM CELLS AND TKI DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA PATIENTS: INTERIM ANALYSIS OF PROSPECTIVE FLOWER-TFR STUDY

EHA Library, Anna Sicuranza, 294989

ASCIMINIB IN HEAVILY PRETREATED PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME–POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) SENSITIVE TO TYROSINE KINASE INHIBITOR (TKI) THERAPY

EHA Library, Tim Hughes, 294990

MAJOR MOLECULAR RESPONSE IS THE THRESHOLD FOR NGS ANALYSIS AND RESISTANT BCR-ABL1 MUTATION DETECTION IN CML

EHA Library, Katerina Machova, 294991

INTERIM ANALYSIS FROM THE OPTIC TRIAL, A DOSE-RANGING STUDY OF 3 STARTING DOSES OF PONATINIB

EHA Library, Jorge Cortes, 294992

DASATINIB PLUS PEG-INTERFERON ALPHA 2B COMBINATION IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: 48-MONTHS RESULTS OF A PHASE 2 STUDY ON BEHALF OF THE FRENCH GROUP OF CML (FI-LMC)

EHA Library, Lydia ROY, 294993

HIGH LEVEL OF SUCCESSFUL TKI DISCONTINUATION OUTSIDE CLINICAL TRIALS - A POPULATION-BASED STUDY FROM THE SWEDISH CML REGISTRY

EHA Library, Hjalmar Flygt, 294994

INTEGRATED LANDSCAPE OF GENE MUTATIONS AND COPY NUMBER ALTERATIONS IN CLONAL HEMATOPOIESIS: ANALYSIS IN 10,852 JAPANESE INDIVIDUALS

EHA Library, Ryunosuke Saiki, 294995